Human coronavirus HKU1 3C-like protease (hCoV-HKU1 3CLpro) (hCoV-HKU1 3CLpro)

Human coronavirus HKU1 3C-like protease (hCoV-HKU1 3CLpro), also known as the main protease (Mpro) or non-structural protein 5 (nsp5), is a critical enzyme for the replication and maturation of the hCoV-HKU1 virus [NIH, Wikipedia]. As a cysteine protease, it functions as a homodimer to cleave the large viral polyproteins pp1a and pp1ab at 11 specific sites, releasing functional non-structural proteins (nsps 4-16) that are essential for the viral life cycle [NIH]. Because there is no human homolog with similar cleavage specificity—typically recognizing a glutamine residue at the P1 position—3CLpro is considered an ideal target for the development of highly selective antiviral therapies [NIH, Wikipedia]. Inhibitors of this enzyme, such as the broad-spectrum peptidomimetic GC376 and various small molecules, aim to block this proteolytic processing, effectively halting viral proliferation [NIH]. While hCoV-HKU1 typically causes mild respiratory infections like the common cold, its 3CLpro is highly conserved across the Coronaviridae family, making it a focal point for the development of broad-spectrum antivirals and pandemic preparedness [NIH]. The enzyme's catalytic mechanism involves a conserved Cys-His dyad, which is the primary site for covalent inhibition by many drug candidates [NIH, RCSB PDB]. Clinical interest in this target has expanded significantly following the COVID-19 pandemic, as inhibitors developed for SARS-CoV-2 often show cross-reactivity with the HKU1 protease [ChemRxiv, NIH]. Monitoring viral load and protease activity serves as a key method for evaluating the efficacy of these therapeutic interventions [NIH].

Other names

Main proteaseMproNon-structural protein 5nsp53C-like proteinaseC30 endopeptidasePeptidase C30

Inhibition of the 3C-like protease prevents the cleavage of viral polyproteins pp1a and pp1ab into functional non-structural proteins, thereby blocking viral replication and transcription [NIH, Wikipedia]. Inhibitors bind to the active site, often covalently to the catalytic Cys145 residue, blocking this proteolytic processing and preventing the formation of the viral replication complex [NIH].